Strategic partnerships Position Selux Diagnostics as a partner for hospital systems and government programs focusing on antimicrobial resistance and rapid sepsis diagnostics. Leverage BARDA funding history and FDA pivotal trial progress to open conversations with procurement teams, clinical decision support vendors, and national health initiatives.

Hospital impact Highlight the platform’s potential to reduce hospital length of stay, lower hospital-acquired infections, and speed targeted therapy within a day of hospital entry. Use these clinical benefits to create value-based proposals for hospital administrators, infectious disease units, and performance improvement programs.

Funding momentum Capitalize on recent and ongoing funding rounds including convertible debt and multi-million rounds led by RA Capital, Sands Capital, Northpond Ventures. Offer pilot collaborations or co-development agreements aligned with investors’ interests in rapid diagnostics and antimicrobial stewardship.

Clinical trial readiness Leverage the ongoing pivotal FDA trial and BARDA-backed programs as proof points for regulatory and real-world efficacy. Propose advisory roles, data-sharing partnerships, or early-access pilots with academic medical centers to accelerate validation and deployment.

Go-to-market readiness Target health systems and hospital networks with a scalable, cloud-enabled NGP platform. Emphasize integration with existing tech stacks (AWS, Azure, Google Cloud, NetSuite) and collaborative opportunities with clinical labs, IT, and supply chain teams to streamline adoption and reimbursement strategies.